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ABSTRACT 
Background Medication administration errors (MAEs) are a problem, yet methodological variation 
between studies presents a potential barrier to understanding how best to increase safety. Using 
the UK as a case-study, we systematically summarised methodological variations in MAE studies, 
and their effects on reported MAE rates.  
Methods Nine healthcare databases were searched for quantitative observational MAE studies in 
UK hospitals. Methodological variations were analysed and meta-analysis of MAE rates performed 
using studies that used the same definitions. Odds ratios (OR) were calculated to compare MAE 
rates between intravenous (IV) and non-IV doses, and between paediatric and adult doses.  
Results We identified 16 unique studies reporting three MAE definitions, 44 MAE subcategories 
and four different denominators. Overall adult MAE rates were 5.6% of a total of 21 533 non-IV 
opportunities for error (OE) (95% CI 4.6% to 6.7%) and 35% of a total of 154 IV OEs (95% CI 2% 
to 68%). MAEs were five times more likely in IV than non-IV doses (pooled OR 5.1; 95% CI 3.5 to 
7.5). Including timing errors of ±30 min increased the MAE rate from 27% to 69% of 320 IV doses 
in one study. Five studies were unclear as to whether the denominator included dose omissions; 
omissions accounted for 0%–13% of IV doses and 1.8%–5.1% of non-IV doses.  
Conclusions Wide methodological variations exist even within one country, some with significant 
effects on reported MAE rates. We have made recommendations for future MAE studies; these 
may be applied both within and outside the UK.  
Introduction 
Medication errors that result in patient harm, also called preventable adverse drug events, are 
estimated to occur in 1–2% of hospital inpatients.1, 2 Of all types of medication errors, medication 
administration errors (MAEs) are least likely to be intercepted before they reach the patient.3 Most 
hospital inpatients also receive more administrations than prescriptions, thus increasing the 
opportunities for error (OE). According to UK medication incident reports, errors at the 
administration stage account for the majority of patient harm and deaths.4 These data suggest that 
greater efforts are needed to prevent errors at administration.  
To prevent errors, we must identify, measure and understand the problem. However, studies of 
MAEs can be challenging and resource intensive as direct observation is generally required.5 
Methodological variations between studies are well known,5–7 and these can limit interpretation of 
findings. Inconsistent MAE definitions, MAE subcategories, denominator definitions and MAE rate 
calculations exist; these present a potential barrier to interpreting and evaluating the transferability 
of interventions to reduce MAEs. The types of dose studied are also likely to affect the MAE rate. 
Intravenous (IV) doses are widely perceived to be higher risk for MAEs compared with non-IV 
doses; a recent UK report identified MAE rates of 3–8% of non-IV doses and 49–94% of IV doses.8 
However, the true extent of the difference in error rates between IV and non-IV doses is unknown 
as studies used different methods and definitions. It is also widely believed that MAEs are more 
prevalent in children than in adults, but no direct comparison exists.9 Consequently, the effects of 
such commonly accepted risk factors on reported MAE rates have yet to be quantified.  
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There are also important differences between countries in how medication is prescribed, dispensed 
and administered, which can hinder the interpretation of study findings. For example, in the UK, 
nursing staff are responsible for preparing the majority of doses, including IV doses, on the ward. 
By contrast, in the USA, pharmacy staff typically prepare the majority of doses and supply these as 
patient-specific unit-doses. Thus MAEs in the UK would include errors made by the nurse at the 
preparation stage while such preparation-related errors in the USA are more likely to have been 
inherited from the earlier dispensing stage.  
As MAE studies are important but time-consuming and costly to conduct, to maximise their value, 
we conducted a systematic review of UK MAE studies to: (1) summarise the variation in MAE 
definitions, MAE subcategories and denominator definitions, (2) quantify their effect on reported 
MAE rates, (3) use comparable MAE and denominator definitions to determine overall non-IV and 
IV MAE rates for adult and paediatric doses, and (4) quantify the effect of including IV and 
paediatric doses on reported MAE rates. We used one country as a case-study because 
differences between countries in how medications are prescribed, dispensed and administered, are 
also likely to affect the prevalence and types of MAEs identified, and thus any exploration of the 
effects of methodological variation on reported MAE rates.10–12 
Methods 
Setting 
In the UK, medications for hospital inpatients are typically prescribed and administered from paper 
drug charts.13 Electronic prescribing is currently rare for hospital inpatients (although common for 
discharge and primary care prescribing), few hospitals use barcode verification at the point of 
administration and unit-dose drug distribution is not used. Instead, nurses administer medications 
using ward-based stocks, patient-specific multi-dose supplies from the hospital pharmacy, and/or 
patients’ own drugs brought in from home.  
Search strategy 
Nine electronic databases were initially searched for published studies up to and including May 
2010: British Nursing Index (from 1985), Cumulative Index to Nursing and Allied Health Literature 
(from 1981), Embase (from 1980), Health Management Information Consortium (from 1983), 
International Pharmaceutical Abstracts (from 1970), Medline (from 1950), Pharmline (from 1978), 
Science Citation Index Expanded (from 1970), Social Science Citation Index (from 1970). The 
search terms were (medication* OR medicine* OR drug* OR ‘near miss’ OR ‘near misses’) AND 
(error* OR discrepan*) AND adminis* AND (prevalence OR incidence OR harm OR severity OR 
mortality OR morbidity OR ‘adverse event’ OR ‘adverse events’ OR ‘adverse drug event’ ‘ OR 
‘adverse drug events’ OR caus*). ‘Medication error’ was also included as a mapped thesaurus term 
in Medline and Embase. Studies were limited to those conducted in humans and published in 
English. The search was repeated in October 2012 to identify papers published since May 2010, 
however Pharmline was excluded as it was archived shortly after May 2010.  
Study selection 
For both searches, one reviewer (MCM) initially screened all titles and available abstracts. A 
random 10% sample was screened by a second reviewer (BDF) to assess reliability. Only studies 
reporting empirical MAE rates detected using observation methods in UK National Health Service 
(NHS) hospitals were included; observation is generally considered to be the gold standard.5, 14 
Conference abstracts, case-reports, and studies focusing only on anaesthesia, nutrition or a 
specific type of MAE were excluded. Full papers of selected studies were retrieved and further 
examined, including their reference lists. A shortlist of studies was produced; both reviewers 
screened these and the final set of studies confirmed through discussion.  
Data extraction and quality assessment 
The two reviewers independently extracted data using standardised forms and discrepancies 
resolved through discussion. A third reviewer was available if agreement could not be reached. 
Where necessary, authors were contacted for missing information. The quality of each study was 
independently assessed by the two reviewers using published criteria which are specific to studies 
measuring MAE rates.5 We also added criteria for reporting: (1) whether or not IV administrations 
were included and (2) whether or not paediatric doses were included, as pilot work indicated that 
not all studies reported this information.  
Data analysis 
MAE definitions, subcategories and denominator definitions were compared and summarised 
descriptively. The effect of specific MAE definitions, MAE categorisation and denominator 
definitions on reported MAE rates was calculated where data were available. A meta-analysis15 of 
reported MAE rates from studies that used the same MAE and denominator definition was 
conducted using a random-effects model. An overall MAE rate was calculated separately for non-
IV and IV data; for studies that included both types of doses, separate MAE rates were extracted 
where possible. For studies conducted in multiple countries, only UK data were extracted. 
Heterogeneity was assessed by calculating the I2 index.15 OR were calculated to assess the effect 
of IV versus non-IV doses and paediatric versus adult doses on MAE rates, [Page 280 ] where 
the same error and denominator definitions were used.  
Results 
We identified 2025 studies: 109 full articles were retrieved and 24 potentially relevant studies were 
subsequently shortlisted. There was 100% agreement between the two reviewers on initial 
inclusion versus exclusion of a 10% sample (n=203 studies). Of the 24 shortlisted studies, four 
were excluded because: an MAE rate could not be extracted from two studies,16 ,17 one was 
conducted in a non-NHS hospital,18 and the method of MAE detection could not be ascertained in 
another.19 Twenty studies 10 ,11 ,14 ,20–36 therefore met our inclusion criteria. Of these, four 14 ,33 ,34 ,36 
analysed data from previous studies; 26 ,28 ,30 ,35 a final 16 unique studies were included. A third 
reviewer was not required.  
Characteristics and quality of studies 
The characteristics of the 16 included studies are outlined in figure 1 and table 1. The majority 
were descriptive and conducted in adult settings. Generalisability was limited in eight studies as 
these were conducted in: (1) only one or two wards, 22 ,23 ,25–27 ,29 ,30 (2) wards that received a 
hospital-specific intervention, 29 ,30 or (3) an unknown number and type of wards.11 
In relation to the quality criteria, ten studies reported clear definitions and methods for determining 
the MAE rate; six did not. Specifically, the following were unclear: (1) the number of MAEs possible 
per dose, 20 ,21 ,31 (2) whether or not dose omissions were included in the denominator,11 ,20 ,21 ,28 ,31 
and (3) whether or not ‘extra doses’(as defined by Allan and Barker),5 were included in the 
denominator. 11 ,20 ,24 ,28 ,31 Participants were told the study objectives in three studies, were not 
informed in three and partially informed in ten. Observers were pharmacists in 14 studies, a 
pharmacist and pharmacy technician in one 31 and a nurse in another.35 Data were collected by 
one observer in nine studies, two observers in six,10 ,20 ,25 ,26 ,29 ,31 and four pharmacists in another. 30 
Of the seven studies with more than one observer, one26 assessed inter-observer reliability 
(reported in a separate paper),14 one reported that ‘detection of medication errors was comparable 
between the two observers’,10 and five did not report whether or not inter-observer reliability was 
assessed. 20 ,25 ,29–31 Potential sources of variation were explored in some studies: observations at 
specific times of day,22 ,24 ,26 days of the week,22 ,26 time-point of inpatient stay,22 timing of 
administration in relation to when the medication was prescribed,22 and nurse-specific variation.26 
All papers reported whether or not IV doses were studied; three studied both dose types but did 
not report error rates for these separately.20 ,31 ,32 Ten papers did not specify whether adults, 
paediatrics, or both, were studied, however all were confirmed as being conducted in adult settings 
by the relevant authors.  
Clinical severity of MAEs was assessed in eight studies: five 25 ,26 ,28 ,30 ,35 used the validated 
method of Dean and Barber,37 one used an earlier method developed by Dean,38 one involved an 
unreported number of clinical pharmacists and the researcher reaching consensus on whether 
each MAE was minor, moderate or major,24 and one used the judgement of an experienced 
pharmacist researcher to classify each MAE as either minor or potentially serious.29 All severity 
assessments were based on potential (rather than actual) harm.  
 
Figure 1  
Characteristics of 16 observational studies of medication administration errors. Weighted 
font sizes have been used to illustrate approximate proportion of studies between groups 
that contain more than two studies. a One study of parenteral administrations was included 
as all doses observed for intravenous (IV) doses except for one intramuscular and one 
subcutaneous dose. b Three of the 12 studies also presented comparisons with other 
countries.  
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Table 1  
Characteristics of 16 UK observational studies and reported medication administration 
error (MAE) rates 
Study Study 
setting 
Data 
collection 
Were 
participants 
told the 
purpose of 
the study? 
IV or 
non-
IV 
doses 
Sample size Reported 
MAE rate* 
(95% CI) 
Dean et 
al10†  
1 hospital, 
6 wards: 2 
medical, 2 
surgical, 2 
MfE 
Consecutive 
weekday 
drug rounds 
(May and 
June 1993) 
Partially (a 
study of 
medication 
administration 
and work 
Non-
IV 
2756 OE 3.0% (2.4 
to 3.7) 
sampling 
conducted 
concurrently) 
Ridge et 
al20 
1 hospital, 
6 wards: 2 
medical, 2 
surgical, 2 
MfE 
1 week on 
each ward 
(at least 10 
drug 
rounds), 
between 
January and 
April 1993 
No (work 
sampling 
study) 
Both 3312 drug 
administration
s 
3.5% (2.9 
to 4.1) 
Gethins2
1 
1 hospital, 
5 wards: 4 
medical, 1 
renal 
6 week 
period 
No (a time 
and motion 
survey) 
Non-
IV 
2000 drug 
administration
s 
2.8% 
Ho et 
al22 
1 female 
MfE ward 
Two 8-day 
periods with 
1 week 
break in 
between 
Partially (a 
study of the 
problems 
associated 
with the 
medication 
distribution 
system) 
Non-
IV 
2170 OE 5.5% (4.5 
to 6.4) 
Cavell 
and 
Hughes2
3 
2 
hospitals, 
2 medical 
wards 
42 drug 
rounds on 
ward with 
handwritten 
charts (H). 
35 drug 
rounds on 
ward with 
computer-
printed 
administratio
n form (C) 
Partially (a 
study of 
computerised 
prescribing on 
the drug use 
process) 
Non-
IV 
1206 OE (H)  
1295 OE (C)  
5.5% (H)  
5.7% (C)  
Hartley 
and 
Dhillon24 
1 hospital. 
3 wards: 2 
surgical, 1 
medical 
39 
consecutive 
days in June 
and July 
1996 
Partially (a 
study to 
understand 
the constraints 
the nurses 
operated 
under and to 
improve the 
provision of 
information for 
their needs)  
IV 320 
prescribed 
doses 
26.9% 
(20.3 to 
30.7) 
Taxis 
and 
Barber25
‡  
1 hospital, 
2 general 
medical 
5 weekdays 
on each 
ward in May 
and July 
1997. All 
scheduled 
drug rounds 
except 
where two 
nurses 
administered 
Partially (a 
study of 
advantages 
and 
disadvantages 
of each 
system) 
Non-
IV 
842 OE 8.0% (6.2 
to 9.8) 
using 
separate 
trolleys  
Dean and 
Barber26 
1 hospital: 
1 vascular 
surgery 
and 1 
renal 
medical 
ward 
Total 27 
days before 
bedside 
lockers were 
implemented
, and 17 
days post. 
All four 
scheduled 
drug rounds 
7 days a 
week 
(January–
June 1998)  
Partially (a 
study to find 
out how often 
medication 
was 
unavailable, 
could not be 
found, or 
whether any 
other 
problems 
occurred) 
Non-
IV 
3576 OE 
(pre)  
2491 OE 
(post)  
4.3% (pre)  
4.2% 
(post)  
Bruce 
and 
Wong27 
1 acute 
admission
s ward 
4 weeks, 
each 
weekday in 
December 
1998 
No (a study of 
time spent on 
drug 
administration
s) 
IV 
(excep
t 1 
SC, 1 
IM) 
107 OE 10.3% (3.8 
to 14.9) 
Taxis 
and 
Barber28 
2 
hospitals, 
10 wards: 
1 renal, 2 
medical, 1 
CTS, 1 
surgical, 1 
ICU, 1 
oncology, 
1 
neonatal, 
1 CICU, 
and 1 
paediatric. 
6–10 
consecutive 
days on 
each ward 
between 
June and 
December 
1999. 
Included 
weekends 
and all times 
of drug 
rounds on 
each ward  
Partially (a 
study of 
common 
preparation 
and 
administration 
problems of IV 
drugs) 
IV 430 observed 
doses 
49% (45 to 
54) 
Wirtz et 
al11 ‡  
1 hospital. 
Number 
and types 
of ward 
not stated 
6 
consecutive 
days in each 
ward, May–
June 2000 
Partially (a 
study of 
problems 
associated 
with preparing 
and 
administering 
IV drugs) 
IV 77 
preparations, 
63 
administration
s 
22% (prep) 
(13 to 31)  
27% 
(admin) 
(16 to 38)  
Franklin 
et al29 
1 mixed 
medical 
ward 
4 weeks pre 
internet-
education 
for nursing 
staff (June 
2004), 4 
weeks post 
(Oct/Nov 
2004) 
Partially (a 
study of drug 
administration 
problems) 
Both 1188 OE 
(pre)  
1308 OE 
(post)  
6.9% (pre)  
5.0% 
(post)  
Franklin 
et al30 
1 general 
surgical 
ward 
2 weeks pre-
EPMA 
(spring 
2007) and 2 
Partially (a 
study of any 
problems 
associated 
Both 1644 OE 
(pre)  
1178 OE 
(post)  
8.6% (pre)  
4.4% 
(post)  
weeks post-
EPMA 
(spring 
2008) 
with the 
medication 
system) 
Conroy 
et al31 
1 
children's 
hospital. 
Included 
PICU, 
NICU, 
medical, 
surgical, 
ED 
6 weeks, 
usually two 
drug rounds 
each 
weekday 
Yes Both 752 
administration
s 
1.2% 
Ghaleb 
et al32 
5 
hospitals, 
10 wards: 
4 medical, 
1 
adolescen
t, 2PICU, 
2NICU, 
1surgical 
2 week 
period on 
each ward 
(2004/2005) 
each day, 
including 
weekends 
Yes Both 1554 doses; 
2249 OE 
27.6% of 
doses19.9
% of OE 
(17.5 to 
20.7) 
Kelly et 
al35 
4 
hospitals, 
8 wards: 1 
MfE and 1 
stroke 
ward per 
hospital 
March to 
June 2008. 
Morning and 
lunchtime 
drug rounds 
on some 
weekdays 
and 
weekends 
Yes Non-
IV 
2129 OE 10.7% 
 
 
 *Wrong time errors were excluded from reported MAE rates where applicable. 
 †Comparison study of UK and USA hospital (only UK data is presented). 
 ‡Comparison study of UK and German hospital (only UK data is presented). 
 CICU, cardiac intensive care unit; CTS, cardio-thoracic surgery; ED, emergency 
department; EPMA, electronic prescribing and medication administration system; 
ICU, intensive care unit; IM, intramuscular; IV, intravenous; MfE, medicine for the 
elderly; NICU, neonatal intensive care unit; OE, opportunities for error; PICU, 
paediatric intensive care unit; SC, subcutaneous.  
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No obvious trend in MAE rates over time was identified, table 1. A forest plot of non-IV studies 
which used the same MAE definition and denominator also showed no apparent trend in MAE 
rates over time (see online supplementary Appendix 1). A scatterplot of the same studies revealed 
no discernible correlation between MAE rates and sample size (see online supplementary 
Appendix 2).  
MAE definitions 
Three different overall MAE definitions were identified. Fourteen studies 10 ,11 ,20–23 25–30 ,32 ,35 used 
Allan and Barker's definition:5 ‘a deviation from the physician's medication order as written on the 
patient's chart’. Of these, three 11 ,28 ,32 expanded this US-based definition to include ‘any deviation 
from standard hospital policy or the manufacturer's instructions’, and one 35 included three 
additional guidance to evaluate the ‘appropriateness of administration’. These made the definition 
more specific for studying IV doses, paediatric doses and doses administered to patients with 
dysphagia in the UK. One study 24 used a circular definition: ‘error in an administered dose or an 
omitted dose’, and one31 used an outcome-based but general definition: ‘preventable events that 
may cause or lead to inappropriate medication use or patient harm’. Observers intervened to 
prevent all identified MAEs in three studies 23 ,24 ,31 and only for potentially serious errors in the 
remaining 13; all interventions were included as MAEs. We found inconsistencies in what was 
included as an MAE, even when the same definition was used. Four specific variations were 
identified, table 2. The most significant and divisive among researchers was ‘wrong time’ errors. 
Based on data reported in one single-centre study, including wrong time errors of over 30 min from 
the time for which the dose was due increased the MAE rate from 27% to 69% of 320 IV doses.24 
The effect of including wrong time errors in non-IV doses was not assessed as relevant studies did 
not report the number of doses with wrong time errors only. However, including wrong time errors 
is likely to substantially increase the reported MAE rate as doses administered over 60 min from 
the time for which the dose was due occurred in 13–50% of a total of 9054 non-IV doses.10 ,22 ,23 ,35 
MAE subcategories 
Forty-four different MAE subcategories were identified, with a median of 11 per study (range 3–16), 
table 3. In some cases, differences in subcategories reflect different ways of classifying the same 
errors. For example, MAE subcategories such as ‘wrong diluent’ and ‘wrong solvent’ can be 
considered more detailed subcategories of a broader subcategory: ‘wrong preparation technique’. 
Furthermore, in studies where only one MAE was allowed for each dose, none specified the 
hierarchy used to decide how the subcategory was allocated if more than one error was observed 
for the same dose. Although the classification should not affect the overall MAE rate, care should 
be taken when comparing specific MAE subcategories across studies.  
We also found different researchers used the same term to mean different things and different 
terms to mean the same thing. This mainly concerned  
Table 2  
Summary of variations associated with medication administration error (MAE) 
inclusion/exclusion criteria in 16 UK observational studies and their effect on the reported 
MAE rate  
Type of variation in 
MAE 
inclusion/exclusion 
criteria 
Number of 
studies in 
which 
included 
as an MAE 
Number of 
studies in 
which 
excluded 
as an MAE 
Number of 
studies in 
which not 
reported 
Effect of variation on 
reported MAE rate 
Wrong time 621 23 24 
27 32 35 
510 11 20 
22 30 
525 26 28 
29 31 
Including wrong time errors 
of over 30 min from the 
time for which the dose 
was due increased the 
reported MAE rate from 27 
to 69% of 320 intravenous 
doses.24 Other studies did 
not report these data 
separately  
Omission due to 
patient not on ward 
321 23 24 135 1210 11 
20 22 25–
32 
Unknown, as studies did 
not report these data 
separately 
Doses left at the 132 410 23 30 1111 20– These accounted for 2.8% 
patient's bedside 
without nurse 
witnessing 
consumption 
35*  22 24–29 
31 
of 1554 paediatric doses in 
one multi-centre study.32 If 
the frequency of doses left 
at the bedside are similar 
in adult hospital settings, 
then inclusion of these as 
MAEs would potentially 
increase the MAE rate by 
up to 2.8% of doses 
observed  
Omission for clinical 
reasons 
121 622 23 28 
29 32 35 
910 11 20 
24–27 30 
31 
These occurred in 0.2% of 
2000 non-intravenous 
doses in one study21 and 
thus their exclusion in other 
MAE studies is unlikely to 
have a significant impact 
on the reported MAE rate  
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 ‘unordered drug’ errors (also known as ‘unauthorised drug’ and ‘unprescribed drug’). One study 
used ‘unauthorised drug’ to include ‘wrong drug’, ‘wrong patient’ and ‘administration of a drug 
without a valid prescription’.23 However, other studies differentiated ‘unauthorised drug’ from 
‘wrong drug’ by stating that the former involves the administration of a drug where no medication 
order exists, while the latter involves administration of a different drug against an existing 
medication order.11 ,25 ,26 ,29 ,32 ,35 An ‘unauthorised drug’ error is also generally differentiated from an 
‘extra dose’ error which is administering an extra dose of a prescribed drug, for example giving a 
medication twice a day instead of once a day.5 
In some cases, differences in MAE subcategories used may reflect disparities in the types of error 
included. One study considered dose omissions, a common MAE subcategory, as a ‘violation of 
procedure’ and differentiated these from MAEs.31 Including dose omissions in this study would 
increase the MAE rate from 1.2% to 5.6% of 742 drug administrations. There were also studies 
that included some procedural violations within established MAE subcategories, for example not 
wearing gloves was included in a ‘wrong preparation technique’ subcategory,24 ,27 but was not 
included as an MAE in other studies. However, data were not reported separately in the relevant 
studies so we were unable to determine their effect on the reported MAE rate.  
Several studies additionally reported a breakdown of specific MAE subcategories based on the 
reason for error. Although the causes of MAE are outside the scope of this review, these additional 
subcategories were frequently reported and provide an important role for understanding MAE rates. 
For example, ‘omission due to unavailability’ was commonly included as a subset of omissions and 
accounted for 52–67% of omissions from a total of 12,993 non-IV doses 10 ,21 ,22 ,26 
Denominators used to determine MAE rates 
We identified four denominators and three main differences between them which may affect 
interpretation of reported MAE rates. The four denominators were the total number of: (1) OE 
defined as the ‘sum of all doses ordered plus all the unordered doses given’,5 (2) ‘drug 
administrations’, (3) ‘prepared and/or administered doses’, and (4) ‘prescribed doses’. The first 
difference between the denominators is whether or not dose omissions were included. All ten 
studies 10 ,22 ,23 ,25–27 ,29 ,30 ,32 ,35 that used OE and one 24 that used ‘prescribed doses’ as the 
denominator included dose omissions, while it was unclear in the remaining five 11 ,20 ,21 ,28 ,31 
whether or not dose omissions were included. Dose omissions accounted for 0–13% of a total of 
934 IV doses 11 ,24 ,27 ,28 and 1.8–5.1% of a total of 16 465 non-IV doses,10 ,22 ,23 ,25 ,26 ,35 therefore 
excluding dose omissions from the denominator will inflate the reported MAE rate. The second 
difference is whether or not extra doses were included: 10 studies that used OE included extra 
doses in the denominator, but it was unclear in the remaining six. Despite this variation, extra 
doses are relatively rare and therefore unlikely to substantially affect the reported MAE rate. The 
third difference is whether or not each dose was split into preparation and administration. This was 
generally a feature of studies that included IV and/or paediatric doses. Seven of the 10 studies that 
used an OE as the denominator counted one OE per dose 10 ,22 ,23 ,25 ,26 ,29 ,35 (all were studies of 
non-IV doses) and three allowed up to two OEs per dose 27 ,30 ,32 (all included IV doses, two in 
adults and one in paediatrics). In the paediatric study where up to two OEs were possible per dose, 
researchers reported that MAEs occurred in 19.1% of OE and 27.6% of doses.32 The effect of 
allowing up to two OEs per dose in this study therefore resulted in a lower calculated MAE rate.  
MAE rates for non-IV versus IV doses 
A meta-analysis of 21 533 adult non-IV OEs from eight studies10 ,22 ,23 ,25 ,26 ,29 ,30 ,35 revealed MAEs 
occurred in 5.6% of non-IV OEs (95% CI 4.6% to 6.7%). One other MAE rate for non-IV doses was 
extracted but excluded from the meta-analysis as a different denominator was used (MAE rate 3.2% 
of 2000 drugs administered).21 Heterogeneity between studies was relatively low (random effects 
model I2=19%).  
Nine MAE rates for IV doses were extracted; however, we conducted a meta-analysis of three 
MAE rates from two studies only as it was inappropriate to include studies that used different error 
and denominator definitions. MAEs occurred in 35% of a total of 156 adult OEs (95% CI 2% to 
68%).27 ,29 Heterogeneity between studies was low (random effects model I2=0); however, this was 
based on a small sample of IV OEs which resulted in a wide 95% CI. Based on these limited data, 
we estimated IV doses to be five times more likely to be associated with an MAE than non-IV 
doses (pooled OR 5.1; 95% CI 3.5 to 7.5).  
MAE rates for adult versus paediatric doses 
Of the three studies that included paediatric doses, two reported IV and non-IV data together 31 ,32 
and one study combined adult and paediatric IV doses.28 It was thus inappropriate to perform a 
meta-analysis of paediatric MAE rates for comparison with adult MAE rates.  
Discussion 
Methodological variations 
While methodological variations between studies are widely known, no review has systematically  
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Table 3  
Medication administration error (MAE) subcategories included in 16 UK observational 
studies 
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MAE 
subcategories (as 
per terminology 
used in studies) 
De
an 
et 
al1
0 
Rid
ge 
et 
al2
0 
Gethin
s21 
H
o 
et 
al
22 
Cavell 
and 
Hughe
s23 
Hartle
y and 
Dhillo
n24 
Tax
is 
et 
al2
5 
Dean 
and 
Barbe
r26 
Bruc
e and 
Won
g27 
Taxis 
and 
Barbe
r28 
Wir
tz 
et 
al1
1 
Fran
klin 
et 
al29 
Fran
klin 
et 
al30 
Conr
oy et 
al31 
Ghal
eb 
et 
al32 
Kell
y35 
Tot
al 
1 Omission* ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  ✓ ✓ 15 
2 Wrong 
dose/improper 
dose* 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  ✓ ✓ ✓  ✓ ✓ 14 
3 Wrong 
dosage 
form/wrong 
form/wrong 
preparation 
selected/wron
g 
pharmaceutic
al form/wrong 
formulation* 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  ✓ ✓ ✓   ✓ 13 
4 Deteriorated 
drug/expired 
drug* 
(✓
) 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  ✓ ✓ ✓   ✓ 12 
5 Extra 
dose/unordere
d dose* 
✓ ✓  ✓  ✓ ✓ ✓    ✓ ✓  ✓ ✓ 10 
6 Wrong drug ✓   ✓ ✓†  ✓ ✓   ✓ ✓ ✓  ✓ ✓ 10 
7 Unordered 
drug/unauthori
sed 
drug/unprescri
bed drug* 
 ✓   ✓† ✓ ✓ ✓ ✓  ✓ ✓   ✓ ✓ 10 
8 Wrong route* ✓ ✓    ✓  ✓ ✓  ✓ ✓ ✓   ✓ 9 
9 Wrong dose 
preparation/wr
 ✓ ✓ ✓ ✓ ✓   ✓  ✓    ✓  8 
ong 
preparation 
technique/wro
ng 
technique/wro
ng 
preparation* 
10 Other/miscella
neous* 
✓   ✓ ✓      ✓ ✓   ✓ ✓ 7 
11 Wrong patient (✓
) 
 ✓  ✓†     ✓   ✓    4 
12 Wrong rate of 
administration
* 
     ✓   ✓  ✓ ✓     4 
13 Drug 
incompatibility 
        ✓ ✓ ✓ ✓     4 
14 Wrong time 
±30 min* 
  ✓ (**
) 
✓ ✓       (**)    3 
15 Wrong 
administration 
technique* 
    ✓ ✓         ✓  3 
16 Wrong time 
±1 h 
(**) (**)  (**
) 
✓    ✓  (**)  (**)   ✓ 3 
17 Fast IV bolus            ✓ ✓    2 
18 Wrong diluent            ✓ ✓    2 
19 Wrong time—
not specified 
            ✓  ✓  2 
20 Unauthorised   ✓              1 
21 Wrong 
preparation 
  ✓              1 
22 Administration 
of a drug 
without a valid 
prescription 
    ✓†            1 
23 Incomplete 
labeling 
        ✓        1 
24 Wrong base         ✓        1 
solution 
content 
25 Errors in 
solvent/diluent 
         ✓       1 
26 Fast 
administration 
through a 
central line 
         ✓        1 
27 Fast 
administration 
through a 
peripheral line 
         ✓       1 
28 Other 
administration 
errors 
         ✓       1 
29 Other 
preparation 
errors 
         ✓       1 
30 Preparation of 
an 
unauthorised 
drug 
         ✓       1 
31 Preparation of 
wrong dose 
         ✓       1 
32 Preparation of 
wrong drug 
         ✓       1 
33 Wrong dose 
preparation 
          ✓      1 
34 Wrong solvent            ✓     1 
35 Wrong volume 
of diluent 
           ✓     1 
36 Wrong volume 
of solvent 
           ✓     1 
37 Errors with 
inhalers/nebuli
ser 
administration 
             ✓   1 
38 Errors with 
oral/gastrosto
my drug 
administration 
             ✓   1 
39 Errors with IV 
drug 
administration 
             ✓   1 
40 Incorrect rate 
of IV 
administration
s 
              ✓  1 
41 Left drug by 
patient's 
bedside 
without 
checking drug 
administration 
              ✓  1 
42 Omission of 
nurses’ 
signature 
following 
administration 
              ✓  1 
43 Wrong dose 
preparation 
and 
administration 
               ✓ 1 
44 Wrong time 
±2 h 
 (**)  (**
) 
        (**)    0 
Tot
al 
 7 8 9 8 12 11 7 8 12 11 12 16 11 3 12 11  
Types of dose 
observed (non-IV, 
IV, or both types) 
No
n 
IV 
Bot
h 
Non IV No
n 
IV 
Non IV IV No
n 
IV 
Non 
IV 
IV IV IV Both Both Both Both Non-
IV 
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summarised and quantified their effects on reported MAE rates. Using the UK as a case-study, we 
found wide methodological variation even within one country. Some differences reflect the 
objectives of specific studies; the rationale for other differences was less clear. We also quantified 
the effect of some methodological variations on the reported MAE rate. Notably, IV doses were five 
times more likely to be associated with a MAE than non-IV doses. While we recognise the 95% CI 
for the pooled MAE rates for non-IV and IV doses overlap, the 95% CI for the OR does not cross 
zero, suggesting that the odds of error was significantly different for non-IV and IV doses.  
Our findings highlight the importance of considering a number of methodological details when 
interpreting studies of MAE rates. More research is required to quantify other methodological 
effects on reported MAE rates, for example: (1) whether or not nurse participants were fully, 
partially or not informed of the study objectives, (2) type of observer for example, pharmacist 
and/or nurse, and (3) the type of medication order included in studies, for example regular and/or 
‘when required’ medication orders.  
MAE rates and practical implications 
Our meta-analysis revealed an overall MAE rate of 5.6% of non-IV OEs and 35% of IV OEs in UK 
hospitals. Our pooled estimate of the MAE rate for non-IV doses was based on a relatively 
homogenous, large sample of OEs in adult patients from a wide range of settings and therefore 
may be useful for benchmarking and monitoring UK hospital MAE rates. By contrast, there was a 
limited sample and wide CI for IV doses.  
Sub-analysis of MAE rates for non-IV doses showed no apparent trends over the past 15 years. 
However, interpretation is limited as studies cannot be compared directly due to methodological 
variations that exist. Studies measuring MAE rates at frequent regular intervals using consistent 
methods are required to monitor long-term trends; this may require coordination at a local and 
national level in order to maximise the utility of the data collected beyond that of a ‘standalone 
descriptive study’.  
Limited numbers of UK studies and insufficient reporting in all three paediatric studies prevented 
calculation of overall MAE rates for paediatric non-IV and IV doses separately. Future studies 
measuring and reporting separate MAE rates for non-IV and IV doses in paediatrics are required to 
assess the effect of including paediatric doses on reported MAE rates.  
Suggestions for future studies of MAEs 
Based on our findings, we suggest definitions and methods for measuring MAEs be based on 
those used previously, to allow comparison with past findings as well as capturing new errors that 
arise. For studies that include IVs, paediatrics and other doses that require multiple manipulations, 
for example for [Page 287 ]  
Table 4  
Suggested reporting criteria for future studies that involve measuring medication 
administration error (MAE) rates adapted from Allan and Barker5 
Parameter We suggest the following information be reported in future MAE 
studies 
Method of data 
collection 
1. Whether direct observation, incident reports and/or chart review was 
used 
2. Number, profession and experience of data collectors 
3. Whether or not inter-observer reliability was assessed if more than one 
data collector, and how this was assessed  
Type of doses 4. Whether or not intravenous (IV) doses were included 
5. Proportion of IV doses, if both IV and non-IV were included 
6. Whether or not regular, when required and/or ‘once-only’ medication 
orders were included  
Patients 7. Whether adults and/or paediatric patients were studied 
8. Proportion of adult and paediatric doses if both were included  
Medication 
administration 
errors 
9. Operational definition accompanied by a set of guidance with examples 
10. Explicit inclusion and exclusion criteria. Examples include stating 
whether or not the following were considered to be an MAE: i. Time of 
administration in relation to that prescribed (for regular and ‘once-only’ 
medication orders) ii. Omissions for clinical reasons such as those 
determined by the nurse, lack of IV access and patient refusal iii. Omission 
due to patient not on the ward iv. Procedural-related violations such as not 
checking a patient's identity, leaving a dose at the patient's bedside without 
observing administration, not labelling a syringe, administering without a 
valid prescription and not documenting administration v. Errors prevented 
by the observer, patient, nurse and other healthcare professionals 
11. Number of errors possible per dose 
12. Number of doses with at least one error if more than one error is 
possible per dose 
13. Types of medication orders involved: regular, ‘when required’, ‘once-
only’ medication, medications ordered separate to the drug chart  
MAE 
subcategories 
14. Operational definitions for error subcategories used 
15. For studies where each dose can only be associated with one error, 
state the hierarchy for deciding how the MAE category should be allocated 
if more than one error occurs in the same dose 
16. The number of MAE detected in each category  
Denominator 17. Operational denominator definition accompanied by a set of guidance 
with examples 
18. Explicit inclusion and exclusion criteria for including doses in the 
denominator. Examples include stating whether or not the following were 
included in the denominator: i. Omission of a prescribed 
dose ii. Administration of an extra dose of a prescribed drug iii. Leaving a 
dose at the patient's bedside without observing administration iv. Non-
medication items, for example support stockings and dietetic 
products v. Oxygen and other medical gases 
19. Types of medication orders included: regular, ‘when required’, ‘once-
only’ medication, medications ordered separate to the drug chart 
20. Relationship between denominator used and a dose, if dose is not used 
as the denominator 
21. Number of doses excluded from the study  
MAE rate 22. How the MAE rate was calculated 
Other 23. Whether or not the clinical severity of MAEs was assessed, and how 
 
 
patients with dysphagia, we suggest building on the work by Taxis et al 28 by separating MAE 
subcategories according to preparation and administration stage. This will develop our 
understanding of where MAEs occur and allow comparisons to be made across different 
medication doses and systems.  
Based on Allan and Barker's MAE definition 5 we propose subcategories be assigned from the 
perspective of the medication order where practical (rather than the patient's perspective). 
Although the patient's perspective plays a vital role in assessing the quality of healthcare in many 
cases, we advocate the medication order viewpoint to provide a practical approach to categorising 
MAEs which also allows for better comparison with previous studies. The perspective is important 
to distinguish between errors such as administering a ‘wrong drug’ to the right patient (patient 
perspective) and administering the right drug (according to the medication order used at the time of 
administration) to the ‘wrong patient’; the former is an error at the preparation stage and the latter 
is an error at the administration stage.  
To improve the clarity of ‘unordered/unauthorised drug’ errors, we recommend splitting this 
subcategory into three: ‘wrong drug’, ‘wrong patient’ and ‘administration without a medication order’. 
A ‘wrong drug’ error occurs when the incorrect drug is selected against an existing medication 
order, a ‘wrong patient’ error occurs when the correct drug is selected but administered to a 
different patient and ‘administration without a medication order’ is giving a drug to a patient against 
no existing medication order (eg, giving a dose before it has been prescribed on the drug chart).  
The use of OE as the denominator has been advocated for determining medication error rates in 
general 39 and for MAE rates specifically.5 For calculating MAE rates, we recommend using the 
proportion of OE with at least one MAE as we found it to be the most practical and easily 
interpretable. We therefore advocate this calculation be used alone or in addition to other MAE rate 
calculations. In studies where each dose may be associated with more than one OE, the proportion 
of doses given (or omitted) with at least one MAE should also be reported where possible.  
Finally, based on our findings in this review and our experience in conducting observation studies, 
we propose a set of reporting guidance to support future [Page 288 ] researchers, table 4. This 
is intended for use in conjunction with standard good practice for reporting, and is designed to be 
non-prescriptive as a considerable part of a study's design and subsequent reporting will depend 
on the objectives. Further work is needed to evaluate this.  
Limitations 
Few studies of IV doses and substantial heterogeneity meant findings from only two studies were 
used to calculate the overall MAE rate for IV doses and we were also unable to explore the 
differences between adult and paediatric MAE rates. Only UK-based studies were included and 
therefore the overall MAE rates cannot be extrapolated to other countries. Finally, 11 of the 16 
included studies were co-authored by authors of this review. We report this as a potential limitation 
as we recognise that this may be perceived as a source of bias. However, we believe this to be 
also one of the strengths of our review, as our experience has allowed us to review the studies to a 
greater level of detail.  
Conclusion 
We have used one country's literature to summarise methodological variations between studies 
within one country and evaluated their effect on reported MAE rates. Our review was based on the 
UK literature, however our methodological and reporting recommendations can be applied to other 
countries. Overall, our findings can be used by researchers to make future MAE studies more 
transparent and comparable.  
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